Strachan D P, Carrington D, Mendall M A, Ballam L, Morris J, Butland B K, Sweetnam P M, Elwood P C
Department of Public Health Sciences, St George's Hospital Medical School, London SW17 0RE.
BMJ. 1999 Apr 17;318(7190):1035-9. doi: 10.1136/bmj.318.7190.1035.
To investigate the effect of Chlamydia pneumoniae infection on future development of ischaemic heart disease and mortality.
Prospective longitudinal study.
Caerphilly, South Wales.
Plasma specimens were collected during 1979-83 from 1773 men aged 45-59 years. These were tested for IgG and IgA antibodies to C pneumoniae (TW183) by microimmunofluorescence.
13 year mortality and incident ischaemic heart disease events were ascertained from death certificates, hospital records, and electrocardiographic changes at follow up every 4 to 5 years.
642 men (36.2%) had IgG antibodies at a titre of >/=1 in 16, of whom 362 (20.4% of all men) also had detectable IgA antibodies. The prevalence of ischaemic heart disease (a history of past or current disease) at entry was similar at all IgG antibody titres but was positively related to IgA antibody titre. IgA antibody titre was positively correlated with plasma viscosity but not with other cardiovascular risk factors. Incidence of ischaemic heart disease was not associated with either IgG antibody titre or IgA antibody titre, but there were stronger and significant relations of IgA antibodies with all cause mortality and fatal ischaemic heart disease, which persisted after adjustment for conventional cardiovascular risk factors. The odds ratios associated with detectable IgA antibodies were 1.07 (95% confidence interval 0.75 to 1.53) for all incident ischaemic heart disease, 1. 83 (1.17 to 2.85) for fatal ischaemic heart disease, and 1.50 (1.10 to 2.04) for all cause mortality.
This is the first prospective demonstration of an association between IgA antibodies to C pneumoniae, a putative marker of chronic infection, and subsequent risk of death from ischaemic heart disease. In contrast to earlier case-control studies, IgG antibodies were not associated with either prevalent or incident ischaemic heart disease.
研究肺炎衣原体感染对缺血性心脏病未来发展及死亡率的影响。
前瞻性纵向研究。
南威尔士的卡菲利。
1979年至1983年间从1773名年龄在45至59岁的男性中采集血浆样本。通过微量免疫荧光法检测这些样本中针对肺炎衣原体(TW183)的IgG和IgA抗体。
每4至5年进行一次随访,从死亡证明、医院记录和心电图变化中确定13年死亡率和缺血性心脏病发病事件。
642名男性(36.2%)的IgG抗体滴度≥1:16,其中362名(占所有男性的20.4%)也检测到IgA抗体。入组时,所有IgG抗体滴度下缺血性心脏病(既往或当前疾病史)的患病率相似,但与IgA抗体滴度呈正相关。IgA抗体滴度与血浆粘度呈正相关,但与其他心血管危险因素无关。缺血性心脏病的发病率与IgG抗体滴度或IgA抗体滴度均无关联,但IgA抗体与全因死亡率和致命性缺血性心脏病存在更强且显著的关联,在对传统心血管危险因素进行调整后这种关联仍然存在。对于所有缺血性心脏病发病事件,与可检测到的IgA抗体相关的比值比为1.07(95%置信区间0.75至1.53),对于致命性缺血性心脏病为(1.17至2.85),对于全因死亡率为1.50(1.10至2.04)。
这是首次前瞻性证明慢性感染的假定标志物——肺炎衣原体IgA抗体与随后缺血性心脏病死亡风险之间存在关联。与早期病例对照研究不同,IgG抗体与现患或新发缺血性心脏病均无关联。